Processing Your Payment

Please do not leave this page until complete. This can take a few moments.

November 13, 2013

ImmuCell posts net income gain in Q3

The Portland-based biotech firm ImmuCell logged $57,000 in net income in the third quarter of the year, up from a loss of $64,000 posted for the same period last year.

In its unaudited quarterly statement, the company reported $1.24 million in product sales, up from nearly $1.1 million for the period ending Sept. 30 last year. That makes six consecutive quarters of product sales growth that Michael Brigham, the company’s president and CEO, said will support funding to conduct initial test marketing for its product to treat bovine mammary infections, Mast Out, which completed an effectiveness study in 2009.

Year-to-date, the company logged $268,000 in net income, compared with $106,000 in net income by the same time last year.

The price of ImmuCell shares were unchanged, at $4.20, on the NASDAQ exchange in mid-day trading.

Sign up for Enews

Mainebiz web partners

Comments

Register for free to read more articles.

Register Now

Already have an online account? Login

To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy

Allow Cookies